You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國再生醫學(08158.HK)擬3500萬港元出售中國再生醫學組織及中國再生醫院投資管理全部股權
格隆匯 08-11 22:16

格隆匯8月11日丨中國再生醫學(08158.HK)公告,於2020年8月11日,賣方中國生物醫學再生科技有限公司(公司的直接全資附屬公司)與買方奧斯寶化粧品國際有限公司訂立出售協議,據此,賣方有條件同意出售中國再生醫學組織工程有限公司及中國再生醫院投資管理有限公司全部已發行股本,總代價為3500萬港元。

中國再生醫學組織工程有限公司主要從事生產及銷售皮膚科產品及服務;買賣醫療設備;及生產及銷售口腔科產品及其他。中國再生醫院投資管理有限公司主要從事生產及銷售眼科產品。

公司一直在評估集團現有業務,以精簡其業務,藉此提高整體表現及成本效益,以及提升財務表現以維持經營。於過往數年,該等出售集團各自的表現未如理想及錄得累計虧損。公司已比較該等出售集團的業務及公司餘下業務(即化粧品及服務分部、細胞產品及服務分部)、及大健康產品及服務分部等並認為化粧品及服務分部、細胞產品及服務分部、及大健康產品及服務分部等未來的發展及需求空間更優,而該等出售集團業務的競爭將越來越激烈,且預期有關業務的盈利能力不會於未來數年改善。因此,董事認為出售該等出售集團實為良機,可將資源集中於發展預期擁有更優發展及盈利前景的餘下業務,並可精簡集團企業架構及削減營運成本。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account